Navigation Links
Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery'
Date:5/20/2010

Lumenis is sponsoring the Endometriosis Foundation of America’s landmark scientific symposium, ‘Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery’.

(Vocus) May 21, 2010 -- Lumenis Ltd., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced today it is sponsoring the Endometriosis Foundation of America’s landmark scientific symposium, ‘Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery’.

“This sponsorship represents Lumenis’ commitment to support research and generate awareness about an often debilitating disease that affects a large number of women”, stated Dov Ofer, Lumenis Chief Executive Officer. Endometriosis is a disease that can appear anywhere within the abdomen, treatment can be especially difficult on delicate tissues such as the bowel. The surgical treatment requires a high level of precision separating healthy from diseased tissue which is where the UltraPulse CO2 laser makes a unique contribution managing endometriosis.

First Ever Endometriosis Symposium in the US
The Endometriosis Foundation’s inaugural symposium will take place at the prestigious New York Academy of Sciences on May 20th, 2010 as a precursor to the second annual Endometriosis fundraiser, the Blossom Ball. It will be the first scientific conference regarding Endometriosis in the United States. Thought leaders from all around the US will gather to advance the dialogue regarding early intervention, treatment, socioeconomic burdens, and other related topics for Endometriosis.

“Lumenis is proud to be a part of such an important cause. Endometriosis is an unbiased disease that affects women all over the world. We will continue in our efforts to bring women the best treatment options”, stated Caroline Coyle, Lumenis Senior Vice President and General Manager, Surgical Business Unit.

Endometriosis, affecting up to 10% of women, is the disease when endometrial cells travel outside of the uterus and implant themselves on organs. These cells still bleed during a woman’s monthly cycle and can cause excruciating pain, as well as infertility. Often symptoms are brushed off as an exaggerated pain but doctors and patients are recently opening their eyes to this legitimate disease.

UltraPulse CO2 Laser
As more gynecological procedures move to minimally invasive endoscopic or laparoscopic surgery, the use of lasers will also continue to increase. Lumenis has kept pace with this expanding field by collaborating with endoscope, laparoscope and colposcope manufacturers. The UltraPulse SurgiTouch laser system combines the best in CO2 laser technologies and offers the most innovative approach to laser surgery today. No other CO2 laser matches its ease-of-use, versatility, precision, control or performance. The UltraPulse provides reduced thermal damage to surrounding tissues and unparalleled char-free ablation, vaporization, excision or incision of soft tissues for endometriosis treatment. Dr. Camran Nezhat, a pioneer in laparoscopic laser surgery for Endometriosis, who will also be honored at the symposium, added, “The CO2 laser enables expert laparoscopic surgeons to treat the most extensive endometriosis safely, accurately, and effectively."

About Lumenis
Lumenis, one of the world’s largest medical laser companies, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has nearly 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning “Light of Life” highlighting the light which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to: www.lumenis.com.

For further information contact:
Michelle Maydan
Director of Corporate Communications
1-866-569-0597
+972-4-959-9004
Lumenis®, its logo, and UltraPulse are trademarks or registered trademarks of the Lumenis Group of Companies.

# # #

Read the full story at http://www.prweb.com/releases/2010/Endometriosis/prweb4030024.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation
2. Lumenis to Showcase Latest Innovations at the 30th Annual American Society for Laser Medicine and Surgery Meeting (ASLMS) in Phoenix, Arizona
3. SIUE Pain Summit Recommendations Announced Today
4. ABBY Winners Announced & Honored with 2010 Innovations in Healthcare(SM) Awards
5. Wharton Business Plan Competition Michelson Grand Prize Winners Announced
6. Sentinel Life Medicare Supplement – Significant Commission Increase Announced
7. Prestigious recognition award recipients announced by AGA
8. Top OTC/Consumer Healthcare Marketers of 2010 Announced
9. Quarter of a Million Dollar Superfruit Challenge Announced
10. Winners Announced from AMD Alliance International Film Contest
11. Caribbean Cruise Announced by Tahitian Noni International for 2011
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery'
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: